Fig. 9
Phillyrin and CXCR2 antagonist SB225002 treatment alleviates percentage weight loss caused by IAV. Briefly, BALB/c mice were randomized into several groups: Control group (n = 6, Saline-treated), Phillyrin group (n = 6, intraperitoneal injection (i.p.) of 15 mg/kg Phillyrin once a day from 0 day to 4 days without infection ), IAV group (n = 6, intranasally challenged with PR8), IAV + Phillyrin group (n = 6, i.p. of 15 mg/kg Phillyrin once a day from 0 day to 4 days postinfection ), IAV + SB225002 group (n = 6, i.p. of 20 μm SB225002 once a day from 0 day to 4 days postinfection ), IAV + Phillyrin + SB225002 group (n = 6, daily i.p. of 20 μm SB225002 from 1 days pre- to 4 days post-infection and i.p. of 15 mg/kg Phillyrin once a day from 0 day to 4 days postinfection), IAV + oseltamivir group (n = 6, orally administrated with 10 mg/kg oseltamivir once a day from 0 day to 4 days postinfection). Phillyrin and SB225002 was suspended in 0.4% carboxymethylcellulose sodium. The body weight change of each group were observed daily following PR8 challenge for a total of 8 days. Mean ± SD (n = 6/group). One-way ANOVA, # p < 0.05 vs. Control, * p < 0.05 vs. IAV.